Is Harvard Bioscience Inc (HBIO) overvalued? · rev $86.5M
Harvard Bioscience Inc (HBIO) is a medical instruments & supplies company listed on US.
This page asks whether Harvard Bioscience Inc (HBIO) looks expensive on cached numbers — not a short thesis.
Latest reported HBIO revenue for 2025-12-31 was $86.5M. Net income was -$56.7M. Revenue was down 8.1% from 2024-12-31 to 2025-12-31. HBIO currently screens at market cap $20.3M.
HBIO currently screens at market cap $20.3M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next HBIO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the HBIO stock page for the full model, not this heading.
Not investment advice.